Finally, we decided to focus on the risk-associated 17q21.31 region as an initial step, but many interesting candidates for further study emerged from the differential methylation analysis in PSP patients vs. controls, namely the nuclear transcription factor NFYA. The gene discussed is NFYA; the disease is supranuclear palsy, progressive, 1.